08:25 AM EDT, 08/01/2024 (MT Newswires) -- Spectral Medical Inc. ( EDTXF ) , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, on Thursday provided an update on the company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

The company had enrolled 125 patients at end of July, including nine in the month of July, which equals the monthly enrollment record set in June.

With 25 patients still needed to reach full enrollment, the company has entered the final push to finish the Tigris trial, which could come as early as December.